EviCure
Extracellular Vesicles-based Platform for the Treatment of Cancer
Company Overview
Snapshot
Founded in February 2023, EviCure operates with 1-10 employees. The company has raised $700K across three funding rounds from one investor. In January 2024, EviCure secured seed funding from Peregrine Ventures.
Business overview
EviCure is a Health Tech & Life Sciences company developing a novel extracellular vesicle (EV)-based platform technology for cancer treatment. The company leverages AI capabilities and human cancer disease models for in-depth comparative analyses of stem cell subpopulations and secreted EVs to achieve robust anti-tumor effects against a wide range of solid tumors. EviCure's EVs can also serve as vehicles for targeted delivery of RNA-based therapies, peptides, and small therapeutic molecules, generating EVs that target multiple oncogenic pathways. Their product, PL-Ex-1, is designed as an EV treatment against lung cancer, aiming to provide a safe, cost-effective, mutation-agnostic, and stage-independent solution for various lung and other solid tumors.
Log in to access full profile ›Company Intelligence Q&A
- What is EviCure's core focus?
- EviCure is focused on developing an extracellular vesicle (EV)-based platform technology for cancer treatment, leveraging AI and sophisticated human cancer disease models to achieve anti-tumor effects against solid tumors.
- When was EviCure founded?
- EviCure was founded in February 2023.
- What is EviCure's lead product?
- EviCure's lead product is PL-Ex-1, an EV treatment designed for lung cancer and other solid tumors, aiming to be safe, cost-effective, mutation-agnostic, and stage-independent.
- Which investor has participated in EviCure's funding rounds?
- Peregrine Ventures has participated in EviCure's funding rounds, including leading a seed round in January 2024 and providing follow-on funding in April 2025 and September 2025.